Article Versions Notes

Schönfelder K, Möhlendick B, Eisenberger U, Kribben A, Siffert W, Heinemann FM, Gäckler A, Wilde B, Friebus-Kardash J. Early CYP3A5 Genotype-Based Adjustment of Tacrolimus Dosage Reduces Risk of De Novo Donor-Specific HLA Antibodies and Rejection among CYP3A5-Expressing Renal Transplant Patients. Diagnostics. 2024; 14(19):2202. https://doi.org/10.3390/diagnostics14192202

Schönfelder, Kristina, Birte Möhlendick, Ute Eisenberger, Andreas Kribben, Winfried Siffert, Falko M. Heinemann, Anja Gäckler, Benjamin Wilde, and Justa Friebus-Kardash. 2024. "Early CYP3A5 Genotype-Based Adjustment of Tacrolimus Dosage Reduces Risk of De Novo Donor-Specific HLA Antibodies and Rejection among CYP3A5-Expressing Renal Transplant Patients" Diagnostics 14, no. 19: 2202. https://doi.org/10.3390/diagnostics14192202

Schönfelder, K., Möhlendick, B., Eisenberger, U., Kribben, A., Siffert, W., Heinemann, F. M., Gäckler, A., Wilde, B., & Friebus-Kardash, J. (2024). Early CYP3A5 Genotype-Based Adjustment of Tacrolimus Dosage Reduces Risk of De Novo Donor-Specific HLA Antibodies and Rejection among CYP3A5-Expressing Renal Transplant Patients. Diagnostics, 14(19), 2202. https://doi.org/10.3390/diagnostics14192202